Biotechnology has long been an important field of scientific research. But until recently, it has never been formally considered by any military as a significant technological investment opportunity, or a technology that could revolutionize the conduct of war. For example, the Pentagons Defense Science Board (DSB), that helped then Secretary of Defense Harold Brown identify technologies central to thesecond offset strategy in 1976, and helped then deputy Secretary of Defense Robert Work identify AI as the key for thethird offset strategy in 2014, explicitly opted not to include biological threats in itsanalysis of known surprises in 2009. Neither did it include biotechnology in thelist of key investment opportunitiesto avoid surprise in 2013.

However, recent studies by the DSB and the National Security Commission on AI (NSCAI) indicate that the Pentagon has changed its mind. It is now preparing for a new biotech revolution in military affairs (RMA), or a new offset strategy, in order to win the long-term strategic competition with China.

In contrast to its previous studies, theDSBs latest reportpublished in September concludes that, the threats and opportunities presented by new bio-enabled capabilities will be significant, and the DoD must ensure it does not fall behind other nations lest it lose its technological edge to competitors in a field that may play a transformational role. Following the studys recommendations, the DoD established anAssistant Director for Biotechnology in 2019. The NSCAI went so far as toarguethat, the combination of advances in AI and biology have the potential to reshape the global economy for the next century. It reached asimilar conclusionthat Chinas weaponization of biology would pose a significant threat to US national security. And biotechnology would be central to the future geostrategic competition.

Drawing on the first offset and second offsetstrategies, the forthcoming offset strategy is working under the assumption that a combination of AI and biotech might actually transform the conduct of war. This strategy, in essence, will be an effort to build on USs own enduring strengths and exploit Chinas enduring weaknesses and vulnerabilities. The following measures are likely to be employed for this military-technical competition.

First, marshalling international partnerships to develop a strategic technology plan to compete with China. As Michael Brown and William Perry did in the 1970s, the Pentagon will identify the most demanding operational challenges the US and its allies would face in a conventional war versus China, anddevelop a strategic technology planto support this offset strategy. Allies and partners is one of the USs key advantages over China. The US has been creating acoalition of coalitions, or a system of systems with itsallies to compete with China. NSCAI Commissioner Jason Mathenyurgesthe US to coordinate AI developments with NATO and making India the focus of the United States Indo-Pacific AI strategy to counter China. And this is in line withJoe Bidens idea of forging a technological future with its allies.

Second, developing operational concepts and making organizational changes that fully exploit the available technologies. Theinterwar experience suggeststhat militaries that do better in developing operational concepts, and making organizational changes will prevail. US National Defense Strategy (NDS)arguesthat, success no longer goes to the country that develops a new technology first, but rather to the one that better integrates it and adapts its way of fighting. China is relatively slow in creating new concepts of operation, and even slower in making organizational adaptations.PLA Lieutenant General Liu Guozhi, the director of the Central Military Commissions Science and Technology Commission, is frustrated, saying that change of mindset is very hard, overcoming obstacles from interested groups is even harder. But those two problems often exist simultaneously. In other words, it takes China longer to convert technological advances into military capabilities. If the US moves fast enough, China will always be a follower learning from and responding to the USs way of war.

Third, drawing on cold war strategies, the US will resort to grey zone operations in order to impose costs on China.NSDis concerned about Chinas grey zone activities and determined to push back against China with all measures short of war. Inspired by the case ofPolands Solidarity in the 1980s, the US and its allies have launched a global name-and-shame campaign on Xinjiang, Hong Kong, South China Sea issues, as well as Chinese influence operations in Australia. Those information campaigns successfully helped them disrupt Chinas 5G roll-out in Europe. It seems that they will double down on this approach by launching aninformation campaign against China Standards 2035, and astrategic communications campaignto highlight BGIs links to the Chinese government and how China is utilizing AI to enable ethically problematic developments in biotechnology and strengthen international bioethical norms and standards regarding genomics research.

While the Pentagon is pondering on a potential biotech RMA, Chinese analysts are closelymonitoring DARPAs investments, andNATOs interestin this field. They have taken notice of the Presidents Science Advisor,Kelvin Droegemeiers remarks on biodefense, and are aware that the US islooking to play a strong offensive gamein this regard. In short, as it did in the1980s, the Peoples Liberation Army will waste no time to join this biotech RMA if they conclude that the US is already on it. However, biosecurity is an international challenge, in order to avoid a race to the bottom, the two militaries should talk to each other and be more transparent about their biotech advancements and intention.

Featured image by Jarmoluk

Read the original:
Biotechnology: the Pentagon's next big thing | OUPblog - OUPblog

The ability to economically recycle poisonous greenhouse gasses like carbon oxides into valuable products via a biological process is an amazing achievement.

San Francisco and Chicago (PRWEB) December 21, 2020

Today, LanzaTech announced the signing of a new multi-year contract with TeselaGen Biotechnology, extending their relationship through 2025. The two companies have been collaborating since 2016 on the informatics behind high-throughput synthetic biology workflows. Over that time, LanzaTech has continued to experience rapid growth, showing the feasibility to synthesize more than 100 different molecules using its carbon-eating bacteria, and demonstrating the need for a significant scaleup of its R&D operations.

"Designing and optimizing biology is not easy, and we are in a race to recycle more carbon before it is too late. This collaboration with TeselaGen will extend our capabilities and help us achieve our goals", said Dr. Sean Simpson Chief Scientific Officer and Co-founder at LanzaTech. TeselaGen has developed one of the most advanced cloud-based solutions for designing, building, and optimizing complex biological workflows and products. We are enthusiastic about extending our collaboration with the TeselaGen team, added Dr. Michael Kpke, Vice President Synthetic Biology at LanzaTech.

LanzaTech has developed unique wet-lab capabilities, as well as some advanced bioinformatic solutions tailored for optimizing their anaerobic microbes. With input from LanzaTech, we have developed an operating system for biotechnology that can interoperate with existing infrastructure and services, facilitating the flow of information across various services, biotech vendors, external databases, algorithms, and automated equipment. This helps LanzaTech keep tight control of their biological design automation process, from start to finish. We want to enable the biotech industry to iterate faster, helping it reduce costs and time-to-market, said Dr. Eduardo Abeliuk, Chief Executive Officer and Co-founder of TeselaGen.

The ability to economically recycle poisonous greenhouse gas like carbon oxides into valuable products via a biological process is an amazing achievement. We are excited to continue helping this very talented team at LanzaTech push the limits of whats possible through Synthetic Biology, added Michael Fero, Chief Operating Officer and Co-founder of TeselaGen. In particular, we look forward to bringing our recently published iterative machine learning approach to the task of making LanzaTechs microbes even more efficient, he added.

About LanzaTechCarbon recycling company, LanzaTech is a global leader in gas fermentation, making sustainable fuels and chemicals via biological conversion of waste carbon emissions, including industrial off-gases; syngas generated from any biomass resource (e.g., municipal solid waste), organic industrial waste, agricultural waste); and reformed biogas. LanzaTechs expertise in fermentation scale-up, reactor design, machine learning, and synthetic biology has enabled the company to commercialize its recycling process and demonstrate the production of over 100 different chemicals. With global investors and partners, LanzaTech has a pipeline of commercial projects around the world and is working across the supply chain to provide novel circular solutions to mitigate carbon by producing consumer goods that would otherwise come from fresh fossil resources. Founded in New Zealand, LanzaTech is based in Illinois, USA, and employs more than 170 people, with locations in China, India, and Europe. Further information is available at http://www.LanzaTech.com

About TeselaGenTeselaGen is building an artificial intelligence-enabled operating system for biotechnology. TeselaGen's cloud-based solution bridges the gaps between biologists who are designing valuable products - like vaccines, biologic medicines, and sustainably sourced chemicals - lab technicians who are running and optimizing experimental workflows, and bioinformaticians who analyze experimental data and have to recommend new experiments. TeselaGen is privately held and is based in San Francisco, CA. The company has received early recognition in the form of various US National Science Foundation funding awards, a CORFO award, and a Bio-IT World Best Practices Award. TeselaGen uses its proprietary Synthetic Evolution technology to help companies efficiently design and optimize biological products. Follow @teselagen on Twitter and learn more at http://www.teselagen.com

Share article on social media or email:

See the article here:
LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes - PR Web

The 51 rating InvestorsObserver gives to Syros Pharmaceuticals Inc (SYRS) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 60 percent of stocks in the Biotechnology industry, SYRSs 51 overall rating means the stock scores better than 51 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 51 means the stock is more attractive than 51 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Syros Pharmaceuticals Inc (SYRS) stock is higher by 9.3% while the S&P 500 has fallen -0.66% as of 1:34 PM on Friday, Dec 18. SYRS has risen $1.03 from the previous closing price of $11.07 on volume of 392,085 shares. Over the past year the S&P 500 has gained 15.37% while SYRS has risen 94.53%. SYRS lost -$1.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Syros Pharmaceuticals Inc (SYRS) Stock.

Go here to read the rest:
Is Syros Pharmaceuticals Inc (SYRS) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

TipRanks

5G is here. The new networks are online and expanding, and customers individual consumers, institutional users, and industrial applications are starting to take advantage of the new technology. The advantages of 5G are already well-known: faster connections, more efficient upload and download capability, lower latency, greater security. 5G tech is essential for developing the full potential of autonomous vehicles and IoT projects. How it will impact ordinary life remains to be seen.Some of Wall Streets top analysts have been taking the measure of the new network, and its probably effect on related companies and their stocks. Using TipRanks database, weve pulled up the latest data on three such stocks that the analysts have tapped for gains in the growing 5G environment. CommScope Holding (COMM)We will start with CommScope, a hardware provider for network infrastructure. The company produces antennas for building and tower installation, base stations, and outdoor wireless system power supplies. As a holding company, these CommScope products are produced and marketed by subsidiaries, to customers worldwide.The company announced last month a partnership with Nokia on a passive-active antenna platform, promising a faster 5G rollout for customers. And earlier this month, CommScope announced a contract with the city of Wyandotte, Michigan, for networking installation, including 5G, and giving the company access to over 25,000 potential customers.CommScope reported $2.17 billion in Q3 revenue, up 3% year-over-year. The Broadband segment showed 20% year-over-year growth, and the free cash flow hit $350 million. JPMorgans 5-star analyst Samik Chatterjee elaborates on CommScope forward potential: Our constructive view on shares of CommScope is led by expectations for an improving outlook for the Outdoor Wireless Segment which stands positioned to benefit from the ramp in 5G densification efforts for wireless networks, in combination with continuing resilient spending from cable/broadband networks."We expect the pace of investments in the wireline network to continue, led by bandwidth requirements to support peak usage, in addition to tailwinds stemming from initiatives such as RDOF and reclamation of satellite spectrum for 5G," the analyst added.In line with these comments, Chatterjee rates the stock an Overweight (i.e. Buy), and his $18 price target suggests a 35% upside in the coming year. (To watch Chatterjees track record, click here)Chatterjee is broadly in line with the rest of Wall Street, which has assigned COMM slightly more "buy" ratings than "holds" over the past three months -- and sees the stock growing about 19% over the next 12 months, to a target price of $15.80. (See COMM stock analysis on TipRanks)Crown Castle (CCI)The next stock on our list, Crown Castle, operates as a real estate investment trust, owning and managing cell network assets, including towers and transmitter locations. The company boasts over 40,000 towers, 70,000 operational small cells, and 80,000 miles of fiberoptic lines. Crown Castles network is part of the shared infrastructure supporting the wireless communications system in the US.The expansion of 5G networks has been good to Crown Castle, and the company has seen growth and expansion.In November, Crown Castle signed an agreement with DISH, which is looking to expand its 5G footprint. The lease agreement gives DISH rental rights on up to 20,000 towers, and includes fiber transport.Quarterly revenues have held steady between $1.4 and $1.49 billion all year, with Q3, the most recent, coming at the latter value. The company saw site rental revenue gain 4% yoy. Customer rollouts to 5G, and consequent need for additional tower sites, underlies the sound financial results.The sound quarterly results allowed the company to increase its quarterly dividend by 11%. Common share holders now receive $1.33 per common share, annualizing to $5.32 and giving a yield of 3.4%.Deutsche Bank analyst Matthew Niknam sees the DISH deal as part of an overall positive picture for Crown Castle: "CCI is poised to be the early beneficiary of multiple new industry catalysts in upcoming years, including DISH's 5G build and C-Band spectrum deployments.""Specifically, we believe its agreement with DISH for up to 20k sites puts it in a premier position to be the tower partner of choice, at least early on. Our analysis indicates DISH could easily account for 10% of CCI's Tower site leasing revenue by 2027E, with the agreement (conservatively) adding $15/share in value for CCI. Second, with ~70% of CCI's sites located in the top 100 markets, we believe its portfolio over indexes to markets most likely to see initial C-Band builds," the analyst added. To this end, Niknam rates CCI a Buy along with a $180 price target. This figure implies a 17% upside from current levels. (To watch Niknams track record, click here)So, thats Deutsche Bank's view, lets turn our attention now to rest of the Street: CCI's 3 Buys and 2 Holds coalesce into a Moderate Buy rating. Should the $170.25 average price target be met, about 11% upside could be in store. (See CCI stock analysis on TipRanks)Sierra Wireless (SWIR)Based in British Columbia, Canada, Sierra Wireless designs and manufactures wireless equipment for an international customer base. The company products include machine-to-machine and mobile computing devices for use on wireless networks, as well as modems, routers, and gateways for mobile broadband wireless. Sierra holds over 550 unique patents.Sierras focus on machine-to-machine systems make its hardware especially valuable for IoT applications. The company offers 5G capable routers and broadcast solutions for IoT networks, as well as the first 5G enabled vehicle router on the market.Turning to the financials and the stock, we see the company moving in two directions at once. Quarterly revenues have been falling this year, and Q3 came in at just $113 million far down from the $144 million reported in Q2. While the quarter was generally down, the automotive business did show a 3.6% yoy increase.The companys stock, however, has been on an upward trajectory, and with a 49% year-to-date gain has outperformed the S&P 500 index.Among the bulls is Colliers analyst Charles Anderson who calls SWIR a "5G IoT play." Anderson rates the stock a Buy along with a $20 price target. This target indicates the extent of his confidence it implies a 40% one-year upside. (To watch Andersons track record, click here)Backing his stance, Anderson writes, We like the combination here of management/Board upgrades (CEOs that led turnarounds at IDTI and LSCC recently joined the Board); business model transition toward higher margin recurring revenue; 5G product cycle exposure; and depressed valuation relative to both peers and historicals""Sierra is in the process of transforming itself from a low margin supplier of cellular connectivity hardware to a higher margin supplier of full stack cellular IoT (hardware/software/service). This is both a better business model and a more compelling offering to customers," the analyst added.All in all, Sierra has an even split among the recent reviews, 2 Buys and 2 Holds, making the analyst consensus rating a Moderate Buy. (See SWIR stock analysis on TipRanks)To find good ideas for 5G stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more:
Kamada Added to the NASDAQ Biotechnology Index - Yahoo Finance

Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19

SAN FRANCISCO and LONDON, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Healths (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) investigational monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs (one of the major sites of infection).

ACTIV-3 is one of several ongoing trials in the NIHs ACTIV program, an NIH led public-private partnership designed to accelerate development of the most promising treatments and vaccine candidates for COVID-19. ACTIV-3 has been designed as a master protocol that allows for the simultaneous evaluation of multiple investigational therapeutics as they become available, but within the same clinical trial structure, across multiple trial sites.

George Scangos, Ph.D., chief executive officer of Vir, said: Recent data suggest that the neutralizing activity of antibodies may be insufficient to protect hospitalized adults from the most severe consequences of COVID-19. We are hopeful that the differentiating factors and broad anti-coronavirus activity of VIR-7831 may allow it to help those patients and add to our preparedness for related coronaviruses that could emerge in the future.

Dr. Hal Barron, chief scientific officer and president R&D, GSK, said: With new infection and hospitalization rates reaching record highs, the world needs multiple options to help combat this pandemic. We are developing solutions to fight this virus, from prevention through treatment, to provide relief from COVID-related illness. Our treatment option, VIR-7831, which has a high barrier to resistance and has the potential to neutralize the virus and kill infected cells, could allow this treatment to be effective for patients in hospital settings, where other antibodies have so far not shown an impact.

Story continues

In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is also being evaluated in the global Phase 2/3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial for the early treatment of COVID-19 in adults at high risk of hospitalization. The Phase 3 part of the COMET-ICE trial is assessing the safety and efficacy of a single intravenous (IV) infusion of VIR-7831 or placebo in approximately 1,300 non-hospitalized participants globally. The primary efficacy endpoint is the proportion of adults who have progression of COVID-19 as defined by the need for hospitalization or death within 29 days of randomization. The COMET clinical development program for VIR-7831 also includes a planned Phase 3 trial for the prevention of symptomatic infection.

ACTIV-3 Clinical Trial DesignThe ACTIV-3 trial arm evaluating VIR-7831 will initially compare 300 participants who have been hospitalized with mild to moderate COVID-19 with fewer than 13 days of symptoms, who will receive either VIR-7831 or placebo. Participants also will receive standard care for COVID-19, including the FDA-approved antiviral remdesivir. Five days after dosing, participants clinical status will be assessed, based on need for supplemental oxygen, mechanical ventilation, or other supportive care. If the VIR-7831 treatment arm appears to have a positive benefit:risk profile, the trial will enroll an additional 700 participants, including those who are more severely ill (i.e., adults with organ failure requiring mechanical support, or COVID-19-associated dysfunction of organs other than the lungs). Trial participants will be followed for 90 days following enrollment to analyze their response to treatment. The primary efficacy endpoint is the participants sustained recovery for 14 days after release from the hospital.

About VIR-7831 / GSK4182136VIR-7831 (GSK4182136) is a monoclonal antibody for which preclinical data suggest its ability to neutralize SARS-CoV-2 live virus in vitro and in vivo. The antibody binds to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1 (also known as SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. VIR-7831/GSK4182136 has been engineered with the potential to enhance lung bioavailability and have an extended half-life.

About the Vir and GSK CollaborationIn April 2020, Vir and GSK entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Virs proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSKs expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.

About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit http://www.vir.bio.

About GSK GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit http://www.gsk.com/about-us.

Vir Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, plan, potential, aim, promising and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-7831 in treating hospitalized patients with COVID-19, the potential benefits of participating in the ACTIV-3 trial, the ability of using a combination of a potent effector function and neutralization capabilities in enhancing the efficacy of monoclonal antibodies to treat hospitalized patients, the efficacy and safety of a single intravenous (IV) infusion of VIR-7831, Virs plans around the evaluation of interim analyses and the expected timing of clinical study results for VIR-7831, the ability of VIR-7831 to prevent symptomatic infection, the clinical trial design around ACTIV-3 as well as statements around the potential benefits of Vir and GSKs collaboration in addressing the current COVID-19 pandemic and future outbreaks of the disease. Many factors may cause differences between current expectations and actual results, including delays or failures in planned patient enrollment or retention, clinical site activation rates or clinical trial enrollment rates that are lower than expected, unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to our business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes.

GSK Cautionary Statement Regarding Forward-Looking StatementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSKs Principal risks and uncertainties section of the Q2 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:No. 3888792

Registered Office:980 Great West RoadBrentford, MiddlesexTW8 9GS

View original post here:
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - Yahoo Finance

BALTIMORE Following an investigation conducted by U.S. Immigration and Customs Enforcement (ICE) Homeland Security Investigations (HSI), the U.S. Attorneys Office for the District of Maryland announced today the seizure of two domain names, mordernatx.com and regeneronmedicals.com, which purported to be the websites of actual biotechnology companies developing treatments for the COVID-19 virus. These spoofed websites were used to collect the personal information of individuals visiting the sites, in order to use the information for nefarious purposes, including fraud, phishing attacks, and/or deployment of malware. Individuals visiting those sites now will receive a message that the site has been seized by the federal government and be redirected to another site for additional information.

Our cadre of highly skilled special agents, paired with invaluable private sector partnerships garnered through the National Intellectual Property Rights Coordination Center provide an effective strategy to help identify, disrupt and dismantle illegitimate domains used to defraud potential consumers. said ICEs Homeland Security Investigations Executive Associate Director Derek N. Benner. Under Operation Stolen Promise, ICE HSI utilized its broad investigative authority to protect consumers from the increasing and evolving threat posed by COVID-19-related fraud and criminal activity. Now, under Operation Stolen Promise 2.0, HSIs focus has expanded to combat the next wave of anticipated fraud related to the COVID-19 vaccine and other treatments. This operation illustrates the ongoing efforts of the National Intellectual Property Rights Coordination Center, private industry and international law enforcement agencies in keeping our communities safe and free from corruption. Often, this battle is fought behind the scenes and unknown to the general public. Though, the global population can be assured that our mission remains firmly committed to protecting their health and safety, no matter what.

The U.S. Attorneys Office and our law enforcement partners are committed to bringing to justice the criminals that try to take advantage of this global pandemic to line their pockets at the expense of the most vulnerable, said U.S. Attorney Robert K. Hur. I urge citizens to remain vigilant. Dont provide personal information or click on websites or links contained in unsolicited e-mails. Dont become a victim.

These individuals took advantage of fear during the global pandemic and attempted to steal personal information for nefarious purposes, said HSI Baltimore Special Agent in Charge John Eisert. From the cyber realm to counterfeit medication to financial crime, we are committed to detecting, investigating, and disrupting all types of fraud related to the COVID-19 pandemic.

According to the affidavits filed in support of these seizures, these investigations began in early December 2020, after corporate security for one of the companies located the spoof website and contacted ICE HSIs Intellectual Property Rights Center (IPRC) and the HSI Cyber Crimes Center (C3), and the other website was located during an ongoing operation targeting suspicious publicly reachable websites by ICE HSI C3. The cases were referred to HSI Baltimore for investigation.

Specifically, on December 10, 2020, the Global Head of Corporate Security for a biotechnology company headquartered in Cambridge, Massachusetts, which has developed a COVID-19 vaccine that is awaiting approval by the U.S. Food and Drug Administration (FDA), contacted HSI IPRC and C3 by e-mail to report that the companys Cybersecurity Team had detected the domain name mordernatx.com, a fraudulent replication of the companys website. A review of that websites online content displayed the name and trademarked logos for the biotechnology company. As detailed in the affidavit, the logos, markings, colors, and text of the mordernatx.com webpage show no substantive differences from the genuine company websites landing page, other than the fraudulent website has a slight misspelling of the companys name. However, individuals who click on the Contact Us tab, are redirected to an entry form requesting information such as name, company/institution, title, phone, e-mail, and comments/questions. Additional investigation revealed that the mordernatx.com domain name was registered on about December 8, 2020, through a company headquartered in Kuala Lumpur, Malaysia, with no personal information for the registrar listed.

The second domain name seized, regeneronmedicals.com, was located on December 9, 2020, during an ongoing investigation targeting suspicious publicly reachable websites. Investigators found that the subject domain name contained the name and trademarked logos, and was visually similar to, the webpage of a biotechnology company headquartered in Westchester County, New York, which was granted an emergency use authorization by the FDA for an antibody cocktail used to treat COVID-19 in high-risk patients with mild to moderate COVID-19. Further investigation revealed that the subject domain name contained two e-mail addresses and a telephone number not found on the official company website. The phone number appears to be a Voice over IP (VOIP) number. In addition, the Contact Us page on the regeneraonmedicals.com site directs Healthcare professionals, patients or caregivers requesting specific product information, reporting an adverse event or reporting a product complaint to contact the Medical Department at the VOIP number. The same Contact Us tab also provides a link to submit medical inquiries which directs users to a page that is different from the same page on the official website. Investigators also found that the subject domain name was registered on December 6, 2020, and lists the registrant as an individual residing in Onitsha Anambra, Nigeria.

By seizing these sites, the government has prevented third parties from acquiring the names and using them to commit additional crimes, as well as prevented third parties from continuing to access the sites in their present form.

ICE HSI launched Operation Stolen Promise in April 2020 to protect the Homeland from the increasing and evolving threat posed by COVID-19-related fraud and criminal activity. As of November 25, 2020, the agency has seized more than $26 million in illicit proceeds; made 170 arrests; executed 148 search warrants and analyzed more than 69,000 COVID-19 domain names. Working with U.S. Customs and Border Protection, more than 1,600 shipments of mislabeled, fraudulent, unauthorized or prohibited COVID-19 test kits and other related items have been seized. For its role in the operation, C3 applies technological, operational, and criminal investigative expertise, products, and services to target the criminals and organizations attempting to commit cybercrimes and exploitation related to COVID-19.

Federal law enforcement is united in its efforts to fight against COVID-19 fraud. ICE HSI has identified tips to recognize and report COVID-19 fraud. If you think you are a victim of a fraud or attempted fraud involving COVID-19, you may also call the National Center for Disaster Fraud Hotline at 1-866-720-5721 or for more information e-mail justice.gov/coronavirus.

The rest is here:
ICE investigation led to seizure of two websites of biotechnology companies developing treatments for COVID-19 vaccine - The Newport Daily Express

Zogenix, Inc. (ZGNX) is near the bottom in its industry group according to InvestorsObserver. ZGNX gets an overall rating of 35. That means it scores higher than 35 percent of stocks. Zogenix, Inc. gets a 27 rank in the Biotechnology industry. Biotechnology is number 28 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 35 would rank higher than 35 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Zogenix, Inc. (ZGNX) stock is trading at $20.22 as of 11:01 AM on Friday, Dec 18, a loss of -$0.08, or -0.39% from the previous closing price of $20.30. The stock has traded between $19.87 and $20.41 so far today. Volume today is less active than usual. So far 308,229 shares have traded compared to average volume of 863,394 shares.

Click Here to get the full Stock Score Report on Zogenix, Inc. (ZGNX) Stock.

Read more:
Is Zogenix, Inc. (ZGNX) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 77 puts aTyr Pharma Inc (LIFE) near the top of the Biotechnology industry according to InvestorsObserver. aTyr Pharma Inc's score of 77 means it scores higher than 77% of stocks in the industry. aTyr Pharma Inc also received an overall rating of 62, putting it above 62% of all stocks. Biotechnology is ranked 25 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

aTyr Pharma Inc (LIFE) stock has fallen -1.89% while the S&P 500 has risen 0.1% as of 11:10 AM on Wednesday, Dec 16. LIFE is down -$0.08 from the previous closing price of $4.37 on volume of 89,629 shares. Over the past year the S&P 500 has risen 15.84% while LIFE has risen 7.25%. LIFE lost -$2.65 per share the over the last 12 months.

Click Here to get the full Stock Score Report on aTyr Pharma Inc (LIFE) Stock.

Read the original post:
Is aTyr Pharma Inc (LIFE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI), which became effective prior to market open today.

On the tails of a momentous year, we are pleased to be included in the Nasdaq Biotechnology Index, said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. Index inclusion recognizes our clinical progress and heightened investor awareness as we remain committed to rapidly advancing our pipeline in rare epilepsies and neuropsychiatric disorders.

The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company has also initiated a Phase 3 trial in status epilepticus. For more information visit http://www.marinuspharma.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, anticipate, estimate, intend, believe, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Read the original post:
Marinus Pharmaceuticals Announces Its Addition to the Nasdaq Biotechnology Index - Business Wire

SAN DIEGO, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointment of Christopher (Chris) Kurtz as executive vice president of technical operations. Mr. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development.

We are pleased to welcome Chris to our leadership team at such a pivotal time for our antifungal and antiviral programs, said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. Chriss leadership and deep manufacturing expertise, delivering both biologic and small molecule drugs to market, will be invaluable as we advance rezafungin, currently in pivotal Phase 3 trials, towards filing, and advance our antiviral conjugate (AVC) influenza program to IND filing.

Prior to joining Cidara, Mr. Kurtz served as head of commercial API manufacturing at Gilead Sciences, where he and his team played an instrumental role in the recent launches of products such as Biktarvy and Veklury (remdesivir). He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization projects for drug-device combinations. Prior to that, Mr. Kurtz held a number of leadership positions where he managed the development, scale-up and commercialization of drugs, biologics, medical devices and combination products at various companies, including Monsanto, Nektar Therapeutics, Alza Corporation, Alexza and Novo Nordisk. He has successfully established supply capabilities and navigated products from late-stage development through approval, launch and sustained commercialization. Mr. Kurtz holds a B.S. in chemical engineering from the University of Colorado and is a graduate of the Westinghouse S3G Nuclear Engineering Program. He is also a proud veteran of the US Navy Submarine Force.

Mr. Kurtz commented, Cidaras commitment to the development of novel long-acting therapeutics for serious fungal and viral infections is of vital importance now more than ever. Rezafungin has the potential to become the new standard of care for the treatment and prevention of invasive fungal infections globally, and I look forward to leveraging my manufacturing and supply chain expertise to support a successful launch in the coming years. Additionally, Cidara is leveraging its Cloudbreak platform to create a new class of long-acting antivirals in influenza, RSV and HIV, and I am very excited to work with the Cidara team to advance these programs.

About RezafunginRezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

About Cloudbreak AVCsCidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.

About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit http://www.cidara.com.

Forward-Looking StatementsThis release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as anticipates, expect, may, plan or will. Forward-looking statements in this release include, but are not limited to, statements related to the potential for rezafungin to transform the standard of care in treatment and prevention of invasive fungal infections, as well as the potential of the Cloudbreak platform to create a new class of long-acting AVCs in influenza, RSV and HIV. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidaras clinical trials, impacts of the COVID-19 pandemic on patient enrollment or other obstacles to the development of rezafungin and advancement of Cidaras other development programs. These and other risks are identified under the caption Risk Factors in Cidaras most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on managements assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com

MEDIA CONTACT:Karen OShea, Ph.D.LifeSci Communications(929) 469-3860koshea@lifescicomms.com

Read more:
Cidara Therapeutics Appoints Biotechnology Industry Veteran Christopher Kurtz As Executive Vice President of Technical Operations - BioSpace

Important applications of nanobiotechnology are in the areas of drug discovery, drug development, and drug delivery, and these are collectively referred to as nanodrugs. Nanobiotechnology, particularly the use of nanoparticles, has made significant contributions to drug discovery and development.

Nanoparticles In Biotechnology And Pharmaceuticals Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. It provides a clear understanding of the subject matter and has been accumulated by suing primary and secondary research techniques.The study report presents the market overview as market size, revenue, share, forecast and market drivers. In addition, report offers an in-depth analysis about the product scope and market opportunities and market risks for the participants. The report provides the description about the profile of the top manufacturers of Nanoparticles In Biotechnology And Pharmaceuticals Market.

Get the PDF Sample Copy of this report @: https://www.a2zmarketresearch.com/sample?reportId=88446

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Top Key Players Profiled in this report:

RocheGE HealthcareMerckNovartisAMAG PharmaceuticalsAmgenBausch & LombBiogenCelgeneGileadIpsenLeadiant BiosciencesnanoComposixPacira PharmaceuticalsPfizerShire

Global Nanoparticles In Biotechnology And Pharmaceuticals Market research report offers: Market definition of the global Nanoparticles In Biotechnology And Pharmaceuticals market along with the analysis of different influencing factors like drivers, restraints, and opportunities. Extensive research on the competitive landscape of global Nanoparticles In Biotechnology And Pharmaceuticals Identification and analysis of micro and macro factors that are and will effect on the growth of the market. A comprehensive list of key market players operating in the global Nanoparticles In Biotechnology And Pharmaceuticals market. Analysis of the different market segments such as type, size, applications, and end-users. It offers a descriptive analysis of demand-supply chaining in the global Nanoparticles In Biotechnology And Pharmaceuticals market. Statistical analysis of some significant economics facts Figures, charts, graphs, pictures to describe the market clearly.

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Nanoparticles In Biotechnology And Pharmaceuticals market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Nanoparticles In Biotechnology And Pharmaceuticals markets trajectory between forecast periods.

Regions Covered in the Global Nanoparticles In Biotechnology And Pharmaceuticals Market Report 2021: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get up to 30% Discount on this Premium Report @: https://www.a2zmarketresearch.com/discount?reportId=88446The cost analysis of the Global Nanoparticles In Biotechnology And Pharmaceuticals Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Reasons for buying this report: It offers an analysis of changing competitive scenario. For making informed decisions in the businesses, it offers analytical data with strategic planning methodologies. It offers seven-year assessment of Nanoparticles In Biotechnology And Pharmaceuticals Market. It helps in understanding the major key product segments. Researchers throw light on the dynamics of the market such as drivers, restraints, trends, and opportunities. It offers regional analysis of Nanoparticles In Biotechnology And Pharmaceuticals Market along with business profiles of several stakeholders. It offers massive data about trending factors that will influence the progress of the Nanoparticles In Biotechnology And Pharmaceuticals Market.

Table of Contents:Global Nanoparticles In Biotechnology And Pharmaceuticals Market Research Report 2021-2027Chapter 1 Nanoparticles In Biotechnology And Pharmaceuticals Market OverviewChapter 2 Global Economic Impact on IndustryChapter 3 Global Market Competition by ManufacturersChapter 4 Global Production, Revenue (Value) by RegionChapter 5 Global Supply (Production), Consumption, Export, Import by RegionsChapter 6 Global Production, Revenue (Value), Price Trend by TypeChapter 7 Global Market Analysis by ApplicationChapter 8 Manufacturing Cost AnalysisChapter 9 Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10 Marketing Strategy Analysis, Distributors/TradersChapter 11 Market Effect Factors AnalysisChapter 12 Global Nanoparticles In Biotechnology And Pharmaceuticals Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/enquiry?reportId=88446 If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us:Roger Smith1887 WHITNEY MESA DR HENDERSON, NV 89014sales@a2zmarketresearch.com+1 775 237 4147

About A2Z Market Research:The A2Z Market Research library provides syndication reports from market researchers around the world. Ready-to-buy syndication Market research studies will help you find the most relevant business intelligence.

Our Research Analyst Provides business insights and market research reports for large and small businesses.

The company helps clients build business policies and grow in that market area. A2Z Market Research is not only interested in industry reports dealing with telecommunications, healthcare, pharmaceuticals, financial services, energy, technology, real estate, logistics, F & B, media, etc. but also your company data, country profiles, trends, information and analysis on the sector of your interest.

Go here to see the original:
Nanoparticles In Biotechnology And Pharmaceuticals Market Witness the Growth of billion by 2026 | GE...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 21, 2020. For this years re-ranking of the index, 100 biotech stocks were added and 16 were removed.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB), and which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.

About Legend Biotech

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 800 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting-edge cell therapies for patients in need. We are engaged in a strategic collaboration to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA targeted CAR-T cell therapy for patients with multiple myeloma. This candidate is currently being studied in registrational clinical trials. To learn more about Legend Biotech, visit us on LinkedIn, or on Twitter @LegendBiotech or at http://www.legendbiotech.com.

Cautions Concerning Forward-Looking Statements

This information constitutes forward-looking statements relating to the publication of, and inclusion of Legend in, the NASDAQ Biotechnology Index. Such forward-looking statements reflect the current expectations of Legends management regarding this future event, and involve factors that may cause actual results to be different from such statements. In particular, Legends expectations could be affected by, among other things, changes in the eligibility criteria for the NASDAQ Biotechnology Index or their application.

The information in this press release speaks only as of the date hereof. Legend assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date.

Read the original:
Legend Biotech Added to the NASDAQ Biotechnology Index - Business Wire

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics, Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: ^NBI). Repares addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Companys pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Pol inhibitor programs. For more information, please visit reparerx.com.

SNIPRx is a registered trademark of Repare Therapeutics, Inc.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are forward-looking statements. These statements may be identified by words such as aims, anticipates, believes, could, estimates, expects, forecasts, goal, intends, may, plans, possible, potential, seeks, will and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery of potential product candidates using SNIPRx platform; and the clinical development of the Companys pipeline and its research and development programs, including the anticipated timing of its clinical trials of RP-3500 and RP-6306; and the development of preclinical assets pursuant to the Companys collaboration with Bristol Myers Squibb. These forward-looking statements are based on the Companys expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Companys clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Companys business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Companys actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Companys Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission (the SEC) on November 12, 2020, and its subsequent filings with the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View original post here:
Repare Therapeutics Added to the NASDAQ Biotechnology Index - Business Wire

New York, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Isolation/Cell Separation Market by Product, Cell Type, Cell Source, Technique, Application, End-User - Global Forecast to 2025" - https://www.reportlinker.com/p04315097/?utm_source=GNW With the rising focus on the development of personalized medicine, the number of personalized medications available in the market has steadily increased over the last decade, and this trend is expected to continue in the coming years.

The consumablesaccounted for the highest growth rate in thecell isolationmarket, by productduring the forecast periodBased on product, the cell isolation market is segmented into consumables and instruments.The consumables segment accounted for the largest share in the cell isolation market in the forecasted period.

The increasing investments by companies to develop technologically advanced products as well as the repetitive use of consumables as compared to instruments are the major factors driving the growth of this segment.

Human cells segment accounted for the highest CAGRBased on cell type, the cell isolation market is segmented into human cells and animal cells.The human cells segment accounted for the largest share of the global cell isolation market in the forecasted period.

The increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the high and growing incidence of diseases such as cancer are the major factors driving this segments growth.

Biotechnology and biopharmaceutical companiessegment accounted for the highest CAGRThe cell isolation market is segmented into hospitals and diagnostic laboratories, biotechnology and biopharmaceutical companies, research laboratories and institutes, and other end users based on end users.In 2019, the biotechnology and biopharmaceutical companies segment accounted for the largest share.

The widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology and biopharmaceutical companies, as well as the increasing number of R&D facilities globally are the major factors driving this segments growth.

Asia Pacific: The fastest-growing regioncell isolation marketThe global cell isolation market is segmented into North America, Europe, Asia Pacific, and Rest of the world.The Asia Pacific region is projected to register the highest CAGR during the forecast period.

Growth in this region is expected to be centered on China and Japan. Factors such as the expansion by key market players in emerging Asian countries and the increasing trend of pharmaceutical outsourcing to Asian countries like India and China are driving the growth of the cell isolation market in this region.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1 - 20%, Tier 2 - 45%,and Tier 3 -35% By Designation: C-level - 30%, D-level - 20%, and Others - 50% By Region: North America -35%, Europe - 24%, Asia Pacific - 25%, Rest of the world 16%

Lits of Companies Profiled in the Report: Thermo Fisher Scientific, Inc. (US) Becton, Dickinson and Company Limited (US) Beckman Coulter Inc. (US).Merck KGaA (Germany) Terumo BCT (Japan), GE Healthcare (US) Bio- Rad Laboratories Inc. (US) Corning Inc. (US) Roche Diagnostics (Switzerland) Alfa Laval (Sweden) Miltenyl Biotech (Germany) pluriSelect Life Science (Germany) STEMCELL Technologies Inc. (Canada) Akadeum Life Sciences, Inc (US) Bio- Techne (US), Bio Legend (US) Invent Biotechnologies (US)

Research Coverage:This report provides a detailed picture of the global cell isolation market.It aims at estimating the size and future growth potential of the market across different segments, such as product, celltype, cell source, technique, application, end user, and region.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell isolation market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, trends, and opportunities.

Read the full report: https://www.reportlinker.com/p04315097/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Visit link:
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% - GlobeNewswire

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc.(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market(NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSMFund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Ovid Therapeutics

Ovid Therapeutics Inc.is aNew York-based biopharmaceutical company using its BoldMedicineapproach to develop medicines that transform the lives of patients with rare neurological disorders. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. For more information on Ovid, please visitwww.ovidrx.com.

Contacts

Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com

OR

Investors:Argot PartnersMaeve Conneighton/Dawn Schottlandt212-600-1902ovid@argotpartners.com

Media:Dan Budwick1ABdan@1abmedia.com

Continue reading here:
Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - GlobeNewswire